Hsieng has more than 30 years of experience in the research and development of large molecular pharmaceuticals. Over his long career and growing positions with Amgen Inc., he was instrumental to the discovery and identification of several important protein therapeutic candidates in the Amgen pipeline including novel cytokines and growth factors, Fc-fusion proteins, as well as antibodies and derivatives (such as antibody drug conjugates and bispecific antibodies). He also supported the preclinical/clinical development of these candidates and contributed to numerous IND filings for protein therapeutics and BLA filing for several marketed biologic products. He led a core group to perform protein structural analysis and characterization and to provide CMC analytical support for protein/antibody therapeutics in development.
Hsieng received a PhD in Biochemistry at the University of North Texas. He has authored more than 100 peer reviewed publications and book chapters and is a co-inventor on number of patents on protein biologics and antibodies. He has been invited to teach and speak at numerous conferences and seminars related to protein therapeutics.